Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine?

Therapeutic Drug Monitoring

Volumn 18, Issue 3, 1996, Pages 228-233

  Schütz, Ekkehard ^a,b   Gummert, Jan ^a   Mohr, Friedrich W ^a   Armstrong, Victor W ^a   Oellerich, Michael ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

6 Thioguanine nucleotides; Azathioprine; Heart transplantation; Thiopurine methyltransferase

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; CYCLOSPORIN A; THIOPURINE METHYLTRANSFERASE; THYMOCYTE ANTIBODY; TIOGUANINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CARDIOGENIC SHOCK; DRUG METABOLISM; DRUG MONITORING; ENZYME ACTIVITY; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SEPTICEMIA;

ADOLESCENT; ADULT; AGED; AZATHIOPRINE; ERYTHROCYTES; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTE COUNT; MALE; METHYLTRANSFERASES; MIDDLE AGED; THIOGUANINE;

EID: 0029953165     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199606000-00002     Document Type: Article

References (26)

1. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46:149-54.
2. Anstey A, Lennard L, Mayou SC, Kirby JD. Pancytopenia related to azathioprine, an enzyme deficiency caused by a common genetic polymorphism: a review. J Roy Soc Med 1992;85:752-6.
3. Shaw LM, Yattscoff RW, Bowers LD, et al.. Canadian consensus meeting on cyclosporine monitoring: report of the consensus panel. Clin Chem 1990;36:1841-6.
4. Tidd DM, Paterson ARP. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 1974;34:738-46.
5. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenetic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62.
6. Tinel M, Berson A, Pessayre D, et al. Pharmacogenetics of human erythrocyte thiopurine methyltransferase activity in a French population. Br J Clin Pharmacol 1991;32:729-34.
7. Swanson MA, Schwartz RS. Immunosuppressive therapy: the relation between clinical response and immunologic competence. N Engl J Med 1967;277:163-70.
8. Hasslein HC, Pierce JC, Lee HM, Hume DM. Leucopenia and azathioprine management in renal homotransplantation. Surgery 1972;71: 598-604.
9. Elion G. Biochemistry and pharmacology of purine analogues. Fed Proc 1967;26:898-903.
10. Lennard L, Rees CA, Lilleyman JS, Maddocks JL. Childhood leukemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol 1983;16:359-63.
11. Kelley WN, Rosenbloom FM, Seegmiller JE. Effects of azathioprine on purine synthesis in clinical disorders of purine metabolism. J Clin Invest 1967;46:1518-29.
12. Ohlman S, Lafolie P, Lindholm A, Liliemark J, Tydén G, Peterson C. Large interindividual variability in bioavailability of azathioprine in renal transplant recipients. Clin Transplant 1993;7:65-70.
13. Bergan S, Rugstad HE, Bentdal O, Endresen L, Stokke O. Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment. Ther Drug Monit 1994;16:13-20.
14. Lafolie P, Hayder S, Björk O, Ahström L, Liliemark J, Peterson C. Large interindividual variations in the pharmacokinetics of oral 6-mercaptopurine in maintenance therapy of children with acute leukemia and non-Hodgkin lymphoma. Acta Pediatr Scand 1986;75:797-803.
15. Ding T, Gambertoglio J Amend W, Birnbaum J, Benet L. Azathioprine bioavailability and pharmacokinetics in kidney transplant recipients. Clin Pharmacol Ther 1980;25:250.
16. Burton N, Barnett M, Aherne G, Evans J, Douglas I, Lister A. The effect of food on the oral administration of 6-mercaptopurine. Cancer Chemother Pharmacol 1986;18:90-1.
17. Chocair PR, Duley AD, Simmonds HA, Cameron JS. The importance of thiopurine methyltransferase activity for the use of azathioprine in renal transplant recipients. Transplantation 1992;53:1051-6.
18. Lennard L, Brown CB, Fox M, Maddocks JL. Azathioprine metabolism in kidney transplant recipients. Br J Clin Pharmacol 1984;18:693-700.
19. Weinshilboum RM, Raymond FA, Pazmino PA. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta 1978; 85:323-33.
20. Lennard L. Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells. J Chromatogr 1987;423:169-78.
21. Schütz E, Gummert J, Mohr FW, Oellerich M. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993;341: 436.
22. Lennard L, Lilleyman JS. Are children with lymphoblastic leukemia given enough 6-mercaptopurine? Lancet 1987;2: 785-7.
23. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990;336: 225-9.
24. Salomon DR, Limacher MC. Chronic immunosuppression and the treatment of acute rejection. In: Husenpud JD, Cobanoglu A, Norman DJ, Starr A, eds. Cardiac transplantation: a manual for health care professionals. New York: Springer Verlag, 1991:139-68.
25. Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 1987;41:18-25.
26. Chocair P, Duley J, Simmonds HA, et al. Low dose allopurinol plus azathioprine/cyclosporine/prednisolone, a novel immunosuppressive regimen. Lancet 1993;342:83-4.